Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Psychiatry/Psychology | Neurology
Disease Category: Schizophrenia and Schizoaffective Disorders
Location: United States, IL
A Phase III, multi-center randomized, 24 week, double-blind, parallel group, placebo controlled study to evaluate efficacy and safety of RO4917838 in stable patients with persistent, predominant negative symptoms of schizophrenia treated with antipsychotics followed by a 28 week, double-blind treatment period
The purpose of this research study is to investigate if an experimental drug, R04917838, is effective at reducing negative symptoms of schizophrenia when added to your current antipsychotic treatment.
Please contact Alexian Brothers for more information on participation.
CW ID: 176877
Date Last Changed:
July 22, 2013
Alexian Brothers Hospital Network1786 Moon Lake Boulevard, Suite 200Hoffman Estates, IL 60169Phone: 847-230-3599
Alexian Brothers Hospital Network
If you would like to learn more about participating in this research study, please email the trial contact using the form below.
We value your privacy and your information will only be used by the research center to contact
you regarding this study.
DISCLAIMER: CenterWatch does not conduct clinical research.
CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies,
contract research organizations, clinical research sites and other interested parties. This information
is designed to help patients find clinical trials of interest and contact the research centers
conducting the trials.
Copyright © 1995-2015 CenterWatch.